NKTX
Nkarta, Inc.
Biotechnology · Healthcare · United States
1.56
close · 2026-10-30
value
10
cheaper than peers10
quality
47
stronger fundamentals47
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.45× | 96 |
| earnings yield, 3 years ago | -167.3% | 24 |
| earnings yield, 2 years ago | -153.8% | 23 |
| earnings yield, latest year | -90.4% | 23 |
| earnings yield, 1 year ago | -102.6% | 22 |
| cash flow yield, latest year | -80.5% | 14 |
| cash flow yield, 1 year ago | -93.2% | 13 |
| cash flow yield, 3 years ago | -93.2% | 13 |
| cash flow yield, 2 years ago | -102.3% | 12 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -38.8% | 76 |
| operating margin | 0.0% | 50 |
| debt to equity | 29.7% | 21 |
3 of 4 measures available
Facts
| market cap | $112M |
| free cash flow | -$55.1M |
| employees | 106 |
| first trade | 2020-07-10 |
| next earnings | not reported |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.41 | -1.60 | -2.40 | -2.61 |
| free cash flow | -$89.9M | -$104.1M | -$114.3M | -$104.1M |
| net income | -$104.1M | -$108.8M | -$117.5M | -$113.8M |
| revenue | $0 | $0 | $0 | $0 |